85
2022 ESC/ERS Guidelines for
the Diagnosis and Treatment of
Pulmonary Hypertension
2025 ACC/AHA Guidelines for the
Management of Adults with Congenital
Heart Disease
Bosentan is a class 1 recommendation;
other endothelin receptor antagonists
"should be considered" in patients
with Eisenmenger syndrome (class 2a
recommendations).
All endothelin receptor antagonists are
recommended as initial treatment in
patients with Eisenmenger syndrome (class 1
recommendation).
Phosphodiesterase-5 inhibitors
"should be considered" in patients
with Eisenmenger syndrome (class 2a
recommendation).
All phosphodiesterase-5 inhibitors are
recommended as initial treatment in
patients with Eisenmenger syndrome (class 1
recommendation).
Riociguat "should be considered" in
patients with Eisenmenger syndrome
(class 2a recommendation).
No specific recommendation due to lack of
data.
Initial prostacyclin therapy "should
be considered" in patients with
Eisenmenger syndrome (class 2a
recommendation).
Initial inhaled prostacyclin therapy may be
considered in patients with Eisenmenger
syndrome (class 2b recommendation).
No recommendation No recommendation
